Actinium Pharmaceuticals, Inc. - Product Pipeline Review - 2016

Date: August 24, 2016
Pages: 45
Price:
US$ 1,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A9098BC549DEN
Leaflet:

Download PDF Leaflet

Actinium Pharmaceuticals, Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Actinium Pharmaceuticals, Inc. - Product Pipeline Review - 2016’, provides an overview of the Actinium Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Actinium Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the pipeline therapeutic landscape of Actinium Pharmaceuticals, Inc.
  • The report provides overview of Actinium Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Actinium Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Actinium Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate Actinium Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Actinium Pharmaceuticals, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Actinium Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Actinium Pharmaceuticals, Inc. Snapshot
Actinium Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Actinium Pharmaceuticals, Inc. - Research and Development Overview
Key Therapeutic Areas
Actinium Pharmaceuticals, Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Actinium Pharmaceuticals, Inc. - Pipeline Products Glance
Actinium Pharmaceuticals, Inc. - Late Stage Pipeline Products
Phase III Products/Combination Treatment Modalities
Actinium Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Actinium Pharmaceuticals, Inc. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Actinium Pharmaceuticals, Inc. - Drug Profiles
Iomab-B
Product Description
Mechanism of Action
R&D Progress
Actimab-A
Product Description
Mechanism of Action
R&D Progress

BC-8Y90

Product Description
Mechanism of Action
R&D Progress

BC-8SA

Product Description
Mechanism of Action
R&D Progress
Actimab-B
Product Description
Mechanism of Action
R&D Progress
Actimab-Br
Product Description
Mechanism of Action
R&D Progress
Actimab-C
Product Description
Mechanism of Action
R&D Progress
Actimab-P
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody Conjugate for Hematological Tumor and Oncology
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody Conjugate for Oncology
Product Description
Mechanism of Action
R&D Progress
Actinium Pharmaceuticals, Inc. - Pipeline Analysis
Actinium Pharmaceuticals, Inc. - Pipeline Products by Target
Actinium Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
Actinium Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
Actinium Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
Actinium Pharmaceuticals, Inc. - Recent Pipeline Updates
Actinium Pharmaceuticals, Inc. - Dormant Projects
Actinium Pharmaceuticals, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Bismab-A
Actinium Pharmaceuticals, Inc. - Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Actinium Pharmaceuticals, Inc., Key Information
Actinium Pharmaceuticals, Inc., Key Facts
Actinium Pharmaceuticals, Inc. - Pipeline by Indication, 2016
Actinium Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
Actinium Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
Actinium Pharmaceuticals, Inc. - Phase III, 2016
Actinium Pharmaceuticals, Inc. - Phase II, 2016
Actinium Pharmaceuticals, Inc. - Phase I, 2016
Actinium Pharmaceuticals, Inc. - Preclinical, 2016
Actinium Pharmaceuticals, Inc. - Pipeline by Target, 2016
Actinium Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
Actinium Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
Actinium Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
Actinium Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016
Actinium Pharmaceuticals, Inc. - Dormant Developmental Projects,2016
Actinium Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2016

LIST OF FIGURES

Actinium Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016
Actinium Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
Actinium Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
Actinium Pharmaceuticals, Inc. - Pipeline by Target, 2016
Actinium Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
Actinium Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
Actinium Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
Skip to top


Ask Your Question

Actinium Pharmaceuticals, Inc. - Product Pipeline Review - 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: